“Rx Price Watch Report: Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans: 2017 Year-End Update,” by Leigh Purvis and Dr. Stephen Schondelmeyer (September 2018, .pdf format, 24p.).
www.aarp.org/ppi/info-2016/trends-in-retail-prices-of-drugs.html
“Reducing Potential Overuse of Dementia Drugs Could Lead to Considerable Savings,” by Elizabeth A. Carter and Leigh Purvis (August 2018, .pdf format, 6p.).
www.aarp.org/ppi/info-2018/reducing-potential-overuse-of-dementia-drugs-could-lead-to-consi.html
A. “Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents,” by Chana A. Sacks, ChangWon C. Lee, Aaron S. Kesselheim, and Jerry Avorn (Vol. 320, No. 7, August 21, 2018, p. 650-656).
jamanetwork.com/journals/jama/article-abstract/2697695
B. “Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia,” by Cécilia Samieri, Marie-Cécile Perier, Bamba Gaye, Cécile Proust-Lima, Catherine Helmer, Jean-François Dartigues, Claudine Berr, Christophe Tzourio, and Jean-Philippe Empana (Vol. 320, No. 7, August 21, 2018, p. 657-664).
“Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2016 Average Sales Prices,” (OEI-03-18-00120, August 2018, .pdf format, 12p.).
“Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market,” a hearing held June 26, 2018 (witness statement available in .pdf format, video of the full hearing available at the site, running time 2 hours 13 minutes). Note: The hearing begins at the 20:25 mark.
“The Food and Drug Administration Computed Prescription Drug User Fee Rates Accurately,” (A-05-17-00040, June 2018, .pdf format, 4p.).
“Increases in Reimbursement for Brand-Name Drugs in Part D,” (OEI 03 15 00080, June 2018, .pdf format, 15p.).
oig.hhs.gov/oei/reports/oei-03-15-00080.asp
Links to an abstract are available. For full text availability check your organization’s library. “The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries,” by Frank R. Lichtenberg (w24536, April 2018, .pdf format, 46p.).
“Medication burden attributable to chronic co-morbid conditions in the very old and vulnerable,” by Kelly L. Moore, Kanan Patel, W. John Boscardin, Michael A. Steinman, Christine Ritchie, and Janice B. Schwartz (PLoS ONE 13(4): e0196109. doi.org/10.1371/journal.pone.0196109, XML, HTML, and .pdf format, 14p.).
journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0196109
“Manufactured Crisis: How Devastating Drug Price Increases Are Harming America’s Seniors,” (March 2018, .pdf format, 11p.).
“How Do Prescription Drugs Affect the Use of Other Health Services?” by Gal Wettstein (IB No. 18-3, February 2018, .pdf format, 8p.).
How Do Prescription Drugs Affect the Use of Other Health Services?
Links to an abstract are available. For full text availability check your organization’s library.
A. “Targeting with In-kind Transfers: Evidence from Medicaid Home Care,” by Ethan M.J. Lieber and Lee M. Lockwood (w24267, January 2018, .pdf format, 74p.).
B. “Household Time Use Among Older Couples: Evidence and Implications for Labor Supply Parameters,” by Richard Rogerson and Johanna Wallenius (w24263, January 2018, .pdf format, 55p.).
C. “High-Priced Drugs in Medicare Part D: Diagnosis and Potential Prescription,” by Richard G. Frank and Richard J. Zeckhauser (w24240, January 2018, .pdf format, 41p.).
“Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2006 to 2015,” by Stephen W. Schondelmeyer and Leigh Purvis (December 2017, .pdf format, 16p.).
www.aarp.org/ppi/info-2016/trends-in-retail-prices-of-drugs.html
“No Limit: Medicare Part D Enrollees Exposed to High Out-of-Pocket Drug Costs Without a Hard Cap on Spending,” by Juliette Cubanski, Tricia Neuman, Kendal Orgera, and Anthony Damico (November 2017, .pdf and HTML format, 13p.).
A. “Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia,” by Susan F. Wood, Joanna Podrasky, Meghan A. McMonagle, Janani Raveendran, Tyler Bysshe, Alycia Hogenmiller, and Adriane Fugh-Berman (PLoS ONE12(10): e0186060. doi.org/10.1371/journal.pone.0186060, HTML, XML, and .pdf format, 13p.).
journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0186060
B. “Physical activity and cohabitation status moderate the link between diabetes mellitus and cognitive performance in a community-dwelling elderly population in Germany,” by Anne Fink, Nikolaus Buchmann, Christina Tegeler, Elisabeth Steinhagen-Thiessen, Ilja Demuth, and Gabriele Doblhammer (PLoS ONE12(10): e0187119. doi.org/10.1371/journal.pone.0187119, XML, HTML, and .pdf format, 15p.).
journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0187119
A. “Medicare Part D: A First Look at Prescription Drug Plans in 2018,” by Juliette Cubanski, Anthony Damico, Jack Hoadley, Kendal Orgera, and Tricia Neuman (October 2017, .pdf and HTML format, 21p.).
www.kff.org/medicare/issue-brief/medicare-part-d-a-first-look-at-prescription-drug-plans-in-2018/
B. “Medicare Advantage 2018 Data Spotlight: First Look,” by Gretchen Jacobson, Anthony Damico, and Tricia Neuman (October 2017, .pdf and HTML format, 5p.).
www.kff.org/medicare/issue-brief/medicare-advantage-2018-data-spotlight-first-look/
A. “Shortcomings of Device Claims Data Complicate and Potentially Increase Medicare Costs for Recalled and Prematurely Failed Devices,” (A-01-15-00504, September 2017, .pdf format, 28p.).
oig.hhs.gov/oas/reports/region1/11500504.asp
B. “Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2015 Average Sales Prices,” (OEI-03-17-00360, September 2017, .pdf format, 10p.).
A. “From Research to Standard Practice: Advancing Proven Programs to Support Family Caregivers of Persons Living with Dementia,” by Lynn Friss Feinberg (September 2017, .pdf format, 19p.).
www.aarp.org/ppi/info-2017/from-research-to-standard-practice.html
B. “Rx Price Watch Report: Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans: 2006 to 2015,” by Leigh Purvis and Dr. Stephen Schondelmeyer (September 2017, .pdf format, 30p.).
www.aarp.org/ppi/info-2016/trends-in-retail-prices-of-drugs.html
“Prescription Drug Abuse among Older Adults,” by Olivia Dean (August 2017, .pdf format, 8p.).
www.aarp.org/ppi/info-2017/prescription-drug-abuse-among-older-adults.html
The US Agency for Healthcare Research and Quality has released a new MEPS data file (July 2017, data in .zip or self decompressing [.exe] ASCII text and SAS Transport format, with documentation in HTML and .pdf format, and SAS and SPSS programming statements in ASCII format).
– MEPS HC-178A: 2015 Prescribed Medicines File
meps.ahrq.gov/mepsweb/data_stats/download_data_files_detail.jsp?cboPufNumber=HC-178A
“Improving Prescription Drug Safety for Canadian Seniors,” by Nicole F. Bernier (No. 61, January 2017, .pdf format, 19p.).
“Rx Price Watch Report: Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans: 2006 to 2015,” by Leigh Purvis and Dr. Stephen Schondelmeyer (December 2016, .pdf format, 30p.).
www.aarp.org/ppi/info-2016/trends-in-retail-prices-of-drugs.html
“Generic Drugs Under Medicare: Part D Generic Drug Prices Declined Overall, but Some Had Extraordinary Price Increases,” (GAO-16-706, August 2016, .pdf format, 52p.).
“CMS Should Address Medicare’s Flawed Payment System for DME Infusion Drugs,” (OEI-12-16-00340, September 2016, .pdf format, 11p.).
“Use of medicines by older people with type 2 diabetes,” (July 2016, .pdf format, 120p.).
A. “Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs,” by Roy H. Perlis and Clifford S. Perlis (PLoS ONE 11(5): e0155474. doi:10.1371/journal.pone.0155474, XML, HTML, and .pdf format, 12p.).
journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0155474
B. “The Incidence and Recurrence of Getting Lost in Community-Dwelling People with Alzheimer’s Disease: A Two and a Half-Year,” by Ming-Chyi Pai and Chih-Chien Lee (PLoS ONE 11(5): e0155480. doi:10.1371/journal.pone.0155480, XML, HTML, and .pdf format, 15p.).
journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0155480
“‘Valeant Pharmaceuticals’ Business Model: the Repercussions for Patients and the Health Care System,” a hearing held April 27, 2016 (witness statement available in .pdf format, video of the full hearing available at the site, running time 3 hours 1 minute). Note: Hearing begins at the 9:54 mark and ends at the 3:10:19 mark
“Sudden Price Spikes in Decades-Old Rx Drugs: Inside the Monopoly Business Model,” a hearing held March 17, 2016 (witness statements available in .pdf format, video of the full hearing available at the site, running time 3 hours 14 minutes). Note: Hearing begins at the 18:03 mark and ends at the 3:32:05 mark.
“Average Manufacturer Prices Increased Faster Than Inflation for Many Generic Drugs,” (A-06-15-00030, December 2015, .pdf format, 7p.).
“Sudden Price Spikes in Off-Patent Drugs: Perspectives from the Front Lines,” a hearing held December 9, 2015 (witness statements in .pdf format, video of the full hearing available at the site, running time 1 hour 59 minutes). Note: Hearing begins at the 14:35 mark.
“Rx Price Watch Report: Trends in Retail Prices of Specialty Drugs,” by Leigh Purvis and Dr. Stephen Schondelmeyer (November 2015, .pdf format, 29p.).
www.aarp.org/ppi/info-2015/trends-in-retail-prices-of-specialty-drugs.html
Links to an abstract are available. For full text availability check your organization’s library.
A. “Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D,” by Abby Alpert, Darius Lakdawalla, and Neeraj Sood (w21714, November 2015, .pdf format, 66p.).
B. “Work Incentives in the Social Security Disability Benefit Formula,” by Gopi Shah Goda, John B. Shoven, and Sita Slavov (w21708, November 2015, .pdf format, 41p.).
“The Economic Burden of Out-of-Pocket Medical Expenditures Before and After Implementation of the Medicare Prescription Drug Program,” by Ayse Akincigil and Karen Zurlo (Working Paper No. 2015-28, November 2015, .pdf format, 20p.). Note: Links to the abstract and the full text of the paper available at:
Note: The link below is to the table of contents for the current issue of JAMA (Vol. 314, No. 17, November 3, 2015). Check with your organization’s information center for availability.
jama.jamanetwork.com/issue.aspx?journalid=67&issueid=934629&direction=P
“Trends in Prescription Drug Use Among Adults in the United States From 1999-2012,” by Elizabeth D. Kantor, Colin D. Rehm, Jennifer S. Haas, Andrew T. Chan, and Edward L. Giovannucci (p. 1818-1830).
“Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study,” by Mary E. Tinetti, Gail McAvay, Mark Trentalange, Andrew B. Cohen, and Heather G. Allore (Vol. 351, No. 8028, .pdf and HTML format, BMJ 2015;351:h4984).
“Medicare Part D at Ten Years: The 2015 Marketplace and Key Trends, 2006-2015,” by Jack Hoadley, Juliette Cubanski, and Tricia Neuman (October 2015, .pdf format, 59p.).
kff.org/medicare/report/medicare-part-d-at-ten-years-the-2015-marketplace-and-key-trends-2006-2015/
A. “Sodium Intake and Socioeconomic Status as Risk Factors for Development of Age-Related Cataracts: The Korea National Health and Nutrition Examination Survey,” by Jeong Hun Bae, Doo Sup Shin, Sung Chul Lee, and In Cheol Hwang (PLoS ONE 10(8): e0136218. doi:10.1371/journal.pone.0136218, XML, HTML, and .pdf format, 11p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0136218
B. “Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study,” by Andreas D. Meid, Renate Quinzler, Julia Freigofas, Kai-Uwe Saum, Ben Schöttker, Bernd Holleczek, Dirk Heider, Hans-Helmut König, Hermann Brenner, and Walter E. Haefeli (PLoS ONE 10(8): e0136339. doi:10.1371/journal.pone.0136339, XML, HTML, and .pdf format, 12p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0136339
“To Switch or Be Switched: Examining Changes in Drug Plan Enrollment among Medicare Part D Low-Income Subsidy Enrollees,” by Jack Hoadley, Laura Summer, Elizabeth Hargrave, Samuel Stromberg, Juliette Cubanski, and Tricia Neuman (July 2015, .pdf format, 25p.).
A. “Influence of Retirement on Adherence to Statins in the Insurance Medicine All-Sweden Total Population Data Base,” by Heli Halava, Hugo Westerlund, Maarit Jaana Korhonen, Jaana Pentti, Mika Kivimaki, Linnea Kjeldgard, Kristina Alexanderson, and Jussi Vahtera (PLoS ONE 10(6): e0130901. doi:10.1371/journal.pone.0130901, HTML, XML, and .pdf format, 14p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0130901
B. “Effect of APOE and CD33 on Cognitive Decline,” by Kathleen M. Hayden, Michael W. Lutz, Maragatha Kuchibhatla, Cassandra Germain, and Brenda L. Plassman (PLoS ONE 10(6): e0130419. doi:10.1371/journal.pone.0130419, XML, HTML, and .pdf format, 10p.).
journals.plos.org/plosone/article?id=10.1371/journal.pone.0130419
“Rx Price Watch Report: Trends in Retail Prices of Generic Prescription Drugs Widely Used by Older Americans: 2006 to 2013,” by Dr. Stephen W. Schondelmeyer and Leigh Purvis (May 2015, .pdf format, 29p.).
www.aarp.org/health/drugs-supplements/info-08-2010/rx_price_watch.html
“Medication use and perceptions of GP care in advanced age: Findings from LiLACS NZ,” (March 2015, .pdf format, 13p.).
Links to an abstract are available. For full text availability check your organization’s library.
A. “Long-Term Care Utility and Late in Life Saving,” by John Ameriks, Joseph S. Briggs, Andrew Caplin, Matthew D. Shapiro, and Christopher Tonetti (w20973, March 2015, .pdf format, 48p.).
B. “Testing for Changes in the SES-Mortality Gradient When the Distribution of Education Changes Too,” by Thomas Goldring, Fabian Lange, and Seth Richards-Shubik (w20993, March 2015, .pdf format, 27p.).
C. “Prescription Drug Use under Medicare Part D: A Linear Model of Nonlinear Budget Sets,” by Jason Abaluck, Jonathan Gruber, and Ashley Swanson (w20976, March 2015, .pdf format, 59p.).
D. “The Wealth of Wealthholders,” by John Ameriks, Andrew Caplin, Minjoon Lee, Matthew D. Shapiro, and Christopher Tonetti (w20972, March 2015, .pdf format, 76p.).
“Comparing Average Sales Prices and Average Manufacturer Prices for Medicare Part B Drugs: An Overview of 2013,” (OEI-03-14-00520, February 2015, .pdf format, 12p.).
“Expenditures for the Top Five Therapeutic Classes of Outpatient Prescription Drugs, Medicare Beneficiaries, Age 65 and Older, U.S. Civilian Noninstitutionalized Population, 2012,” by Marc Roemer (Statistical Brief No. 469, February 2015, .pdf and HTML format, 6p.).
meps.ahrq.gov/mepsweb/data_stats/Pub_ProdResults_Details.jsp?pt=Statistical+Brief&opt=2&id=1174
“Does Medicare Part D Save Lives?” by Abe Dunn and Adam Hale Shapiro (Working Paper 2015-04, February 2015, .pdf format, 65p.).
Abstract:
This paper studies the impact of Medicare Part D on mortality for the population over the age of 65. We identify the effects of the reform using variation in drug coverage across counties before the reform was implemented. Studying mortality rates immediately before and after the reform, we find that cardiovascular-related mortality drops significantly in those counties most affected by Part D, while mortality rates for noncardiovascular diseases remain statistically unchanged. Estimates suggest that between 19,000 and 27,000 more individuals were alive in mid-2007 because of the Part D implementation in 2006.
“Are Income-Based Public Drug Benefit Programs Fit for an Aging Population?” by Steven G. Morgan, Jamie R. Daw and Michael R. Law (December 2014, .pdf format, 27p.).
“Strategies Used by Adults to Reduce Their Prescription Drug Costs: United States, 2013,” by Robin A. Cohen and Maria A. Villarroel (Data Brief No. 184, January 2015, .pdf and HTML format, 8p.).
“Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010,” by Frank Lichtenberg (Working Paper No. 5166, January 2015, .pdf format, 17p.). Note: Links to the abstract and the full text of the paper available at:
www.cesifo-group.de/ifoHome/publications/working-papers/CESifoWP/CESifoWPdetails?wp_id=19149834
“Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003–2012,” by Qiuping Gu, Ryne Paulose-Ram, Vicki L. Burt, and Brian K. Kit (Data Brief No. 177, December 2014, .pdf and HTML format, 8p.).
A. “Should Public Drug Plans be Based on Age or Income?” by Colin Busby and Jonathan Pedde (Commentary No. 417, December 2014, .pdf format, 25p.).
www.cdhowe.org/should-public-drug-plans-be-based-on-age-or-income/28146
B. “Paying for the Boomers: Long-Term Care and Intergenerational Equity,” by Ake Blomqvist and Colin Busby (Commentary No. 415, September 2014, .pdf format, 32p.).
www.cdhowe.org/paying-for-the-boomers-long-term-care-and-intergenerational-equity/27499
Powered by WordPress
